SLC16A3 and carcinoma: Fiaschi et al. have found that the prostate cancer cells underwent metabolic reprogramming to support the growth of carcinoma cells that gradually tended to depend on lactate-derived anabolic metabolism by increasing the expression of MCT1 and MCT4 [102].